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Abstract Heart failure (HF) is a major and growing cause of
morbidity and mortality. Despite initial successes, there have
been few recent therapeutic advances. A better understanding
of HF pathophysiology is needed with renewed focus on the
myocardium itself. A new imaging technique is now available
that holds promise. T1 mapping is a cardiovascular magnetic
resonance (CMR) technique for non-invasive myocardial tis-
sue characterization. T1 alters with disease. Pre-contrast
(native) T1 changes with a number of processes such as
fibrosis, edema and infiltrations. If a post contrast scan is also
done, the extracellular volume fraction (ECV) can be mea-
sured, a direct measure of the interstitium and its reciprocal,
the cell volume. This dichotomy is fundamental — and now
measurable promising more targeted therapy and new insights
into disease biology.
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Introduction
Heart failure (HF) is a complex clinical syndrome where the
ability of the heart to supply physiological perfusion to organs
is impaired, either by acquired or inherited disease. The key
biomarker for measuring heart failure is the left ventricular
ejection fraction (LVEF)— but a low ejection fraction and HF
are not synonymous. Common causes are ischemic heart
disease, hypertensive heart disease, valvular heart disease,
diabetes, myocarditis, cardiomyopathies, tachycardia-
induced cardiomyopathy, and systemic diseases with cardiac
involvement. In most HF presentations there is more than one
cause. HF represents one of the most important problems for
both modern medicine and society with massive impact on
individuals and a major annual cost for health systems. The
annual costs for HF care exceed $40 billions in the US, with
the majority spent on hospitalizations for HF [1–3]. Moreover,
hospital discharges for HF remained essentially unchanged
over 10 years [4].
Damage the heart and the whole organism responds —
upregulated renin-angiotensin system changes, haemodynam-
ic and skeletal muscle changes are the most well known.
However, it is the myocardial response that is the most fun-
damental — that of the myocytes and fibroblast (the most
prevalent cells in the myocardium), and extracellular space
changes. These changes may be initially adaptive but may
progress to be maladaptive. Common features of this
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remodelling process are cardiomyocyte hypertrophy, extracel-
lular matrix expansion and composition alteration. Calcium
handling, energy metabolism, contractile function, vascula-
ture and cell viability may also change. These processes
although deeply interwoven may combine into characteristic
myocardial phenotypes which, if we can measure them, may
permit us to split HF up in a subtypes, opening the door for
tailored therapy according to the precise myocardial pheno-
type [5].
There is however a problem. There is no denying the
significant advances in treatment strategies for HF, including
drug and device therapy, cardiac transplantation, and mechan-
ical circulatory support. However, despite these, the prognosis
has not improved in worsening chronic HF, de novo HF and
advanced or end-stage HF, which continue to have high mor-
tality and re-admission rates [2–6]. Whilst the basic biology
has pointed to a host of potential therapeutic targets with
successful phase 2 trials, few of these have translated to phase
3 trial successes. There may be several reasons. Firstly, we
measure the wrong thing — the ejection fraction in defining
HF, despite the fact that 40 % of HF has a preserved LVEF.
Secondly, we group all types of HF together, thereby ignoring
personalised differences in myocardial disease biology. Third-
ly, our early phase trial surrogate endpoints (such as short term
symptoms improving) are not well tied to important outcomes
such as mortality [3]. What is needed is a better practical
understanding andmeasurement of disease biology— fibrosis
and myocyte response to split heart failure into different
groups, with these biomarkers being tied to specific therapies
[2, 3, 7]. This review focuses on a novel technique using
standard cardiovascular magnetic (CMR) scanner, T1 map-
ping, to do this and its potential to act as a disease (rather than
syndrome) biomarker, as a surrogate endpoint in trials and as a
way of monitoring and tailoring therapy once implemented for
better patient outcomes.
Cardiovascular Magnetic Resonance— LGE Technique
In the last 10 years, CMR has provided two key technologies
for HF: anatomical and functional assessment using cine
imaging and tissue characterization for focal abnormalities,
particularly scar imaging using the late gadolinium enhance-
ment technique (LGE). Cine imaging provided a more accu-
rate and reproducible quantification of LVEF, size and mass,
particularly in hearts that were geometrically distorted. The
LGE technique for the first time allowed visualization of focal
scar. When integrated, there was a step change, but perhaps
not a revolution in our understanding of HF. Scar pattern,
particularly in early disease provided insights into the under-
lying causes of myopathy, whilst the extent of scar was
prognostic — and incrementally so over LVEF. The lack of
scar in particular predicted functional recovery following
intervention with resynchronisation (discoordination),
revascularization (hibernation) or with time (stunning). Addi-
tional techniques such as T2-weighted imaging for edema and
T2* imaging for iron quantification added in selected circum-
stances. However, a gap still remained: the LGE technique
could not detect global myocardial changes such as occur in
diffuse fibrosis. In addition, all scars looked the same —
whether there was 50 % or 100 % myocyte loss in a region.
It is in this gap that T1 mapping provides new information.
T1 Relaxation time and LGE Imaging
Magnetic resonance of protons varies between tissues, de-
pending on the macromolecular environment that water finds
itself in. The T1 relaxation time (longitudinal relaxation time,
measured in milliseconds) is a tissue-specific magnetic prop-
erty and is determined by how rapidly protons re-equilibrate
their spins within their environment after been excited by
radiofrequency pulse. T1 varies with measurement technique
and MRI field strength. Regional difference in T1 can be
visualized by T1-weighted sequences following an intrave-
nous bolus of extracellular contrast, gadolinium, to evaluate
myocardial scar or focal fibrosis.
Gadolinium is an extracellular agent not able to enter
through intact cell membrane and cleared from the blood pool
after minutes. In tissue with damaged or dead cells, these
kinetic effects are delayed and there is a higher accumulation
of contrast due to ruptured cell membranes allowing gadolin-
ium to passively diffuse into the cellular compartment. Gad-
olinium changes magnetic properties by shortening T1 of a
tissue. If at this point, a T1-weighted inversion recovery
sequence is performed, with the inversion time (TI) set man-
ually by the operator to null “normal” remote myocardium,
this will appear black and scar tissue white [8].
The LGE technique is now the gold standard test for the
detection of scar across the spectrum of cardiac disease. Its
assessment is reproducible and scar visualization provides a
good indicator of disease etiology whilst scar extent carries
prognostic information, which inmany diseases is incremental
to conventional prognostic markers. In HF, the LGE technique
reduces diagnostic dilemmas but raises new ones: for exam-
ple, it used to be a clinical conundrum that burnt out hyper-
trophic cardiomyopathy (HCM) could mimic dilated cardio-
myopathy. The LGE technique distinguishes these with ease.
However, within the HCM spectrum, whilst in early disease,
the LGE pattern may point to the underlying etiology (e.g.
sarcomeric protein disease, Fabrys etc.) by end stage, all the
diseases start to look the same and scarred out. LGE prognos-
tication is incrementally useful: in a large study (n>1000),
LGE was associated with first hospitalizations for HF after
CMR, death or both across the range of ejection fractions
including preserved EF. Furthermore, even if LVEF was
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severely decreased, those without LGE appeared to have less
risks of hospitalization for heart failure or death [9].
However, the LGE technique has limits. Measuring the
extent of LGE is difficult as different techniques produce
different results, particularly in non-ischemic cardiomyopathy
[10]. The technique is “black and white”—within LGE areas,
complete replacement scar looks the same as 50 % myocyte
loss; and conversely background “normal” myocardium is all
uniformly nulled meaning diffuse remote pathology and fi-
brosis is entirely overlooked. This latter point means the LGE
technique misses global myocardial pathologies — for exam-
ple LGE is an uncommon finding in pressure or volume
overload disease, systemic condition with cardiac involve-
ment, cardio-toxic effect of different agents, diabetes or hy-
pertension cardiac effect even though all are known to have
diffuse fibrosis.
Rapid technical innovations in CMR have generated a
novel parametric mapping field addressing these shortcom-
ings. These methodologies permit the routine acquisition of
quantitative measure of underlying tissue-specific T1 relaxa-
tion rather than relative signal intensities.
T1 Mapping
After recent technical improvements, T1 measurement
(multi-breath-hold or multiple images requiring curve
fitting and processing) has been replaced by T1 mapping.
In a single breath-hold, using various approaches, a T1
colour relaxation map is made [11–13]. Within the map,
each given pixel value directly corresponds its underlying
relaxation time that can be seen (in colour) or more
formally measured, standardized, calibrated to histology
[14••, 15, 16], compared across diseases and with normal
reference ranges [17]. There are two key ways of using T1
mapping: without or before contrast (native T1 mapping);
and with contrast, typically by subtracting the pre and
post maps with hematocrit correction to generate the
extracellular volume fraction (ECV) (Fig. 1).
Native T1
Myocardial native (non-contrast) T1 measures the T1 values
from the extracellular and intracellular compartments. Mea-
surement requires no exogenous contrast administration, mak-
ing it feasible even in patients with severe kidney dysfunction.
T1 increases with pathologies where increased water is pres-
ent such as edema [18, 19] (Fig. 2e), focal or diffuse fibrosis
[16] (Fig. 2f) and amyloidosis [20]. T1 reduces in the presence
of lipid [21] and iron overload (Fig. 2b) [22, 23]. Using a
short, single breath-hold, T1 mapping sequence to obtain
native T1 values may complement in diseases where the
LGE technique works (such as infarction) [18, 19, 24, 25]
but more importantly may detect pathology otherwise missed
by LGE technique, such as a pan-myocarditis [26]. In diffuse
fibrosis, native T1 changes can be subtle. In other diseases, the
changes may be very large indeed — two exemplar diseases
with gross but opposite T1 changes are informative.
In Anderson-Fabry disease (AFD), where mutations of the
α-galactosidase gene result in intracellular lipid accumulation
and left ventricular hypertrophy (LVH), the native T1 falls,
and falls by many standard deviations (Fig. 2c). This fall
appears to be a direct measurement of myocyte lipid storage,
which had not previously been measurable. In every other
cause of LVH so far explored (HCM, amyloid, aortic stenosis
(AS), hypertension) T1 increases, meaning that a low T1
absolutely distinguishes AFD from all other causes of LVH
with no apparent overlap [21], and with superior discrimina-
tion to other factors [27]. In AFD patients without LVH, up to
half of patients have a low T1, suggesting that T1 is a marker
of early cardiac involvement. One caveat of interest is that
these findings are in the septum in AFD patients without heart
failure. In the basal infero-lateral wall a large number of
patients have an area of high T1 — in the area that LGE is
Fig. 1 T1 maps (using MOLLI [39•], short axis view) in a healthy
volunteer pre-contrast (left) and post-contrast (centre), both measured in
milliseconds. For the ECV map (right), each pixel has a value of the
interstitial volume as it was calculated from the two T1 maps. The region
of interest (white) showing a normal ECVof 27 %
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found, with a surrounding area of normal T1, suggesting a
four step pathological progression from normal to low to
pseudo-normalized to high T1. Whether this is true (perhaps
the infero-lateral wall is never low) and whether this is a pan-
myocardial process leading to heart failure is currently un-
known. Combined, these observations raise the possibility of
T1 mapping for early diagnosis, as a surrogate endpoint in
therapy trials and to monitor therapy, but much more work is
needed.
In cardiac AL amyloidosis (Fig. 2d), clinically observed
cardiac involvement is associated with marked elevations in
native T1. These correlate with markers of LV mass, LV
systolic dysfunction and markers of diastolic dysfunction
(E/E’ and E deceleration time). Clinically, AL amyloid cardiac
involvement is classified by echocardiography and bio-
markers into absent, possible and definite involvement. T1 is
elevated not only in the definite cardiac involvement patients,
but also in the possible and no cardiac involvement patients,
at a lower level, suggesting both that T1 measurement may
add value, but also that amyloid infiltration is an earlier
phenomenon in this systemic disease than was previously
thought [20]. The other main type of ventricular myocardial
amyloid is associated with transthyretin amyloid (TTR;
ATTR for amyloid from TTR). In ATTR, preliminary data
detect T1 elevations also. These elevations are far higher than
fibrotic diseases such as in AS, but appear not as high as in
AL amyloid [28].
Native T1 is a feasible clinical tool. However, there are
some specific hurdles to be overcome for clinical utility.
Whilst pathology influences T1, so does magnet field
strength and the precise approach used to its estimation
[29]. These differences between approaches may be higher
than the differences between health and disease pathology.
Therefore at this time whilst technical developments are
progressing at pace, normal reference ranges are needed for
each approach and ideally for every centre. Moreover, the
signal acquired is a composite signal — generated by both
interstitium and myocytes. The use of an extracellular contrast
agent adds another dimension to T1mapping and the ability to
distinguish and quantify intracellular and extracellular
compartment.
Extracellular Volume Fraction (ECV)
Measuring the T1 time, following the administration of an
extracellular contrast agent (gadolinium chelates), generates
the possibility to dichotomize the myocardium into its cellular
and extra-cellular components. In early studies, the absolute
value of T1 post-contrast was used [30] but this has some
limitations. This value is affected by renal clearance, gadolin-
ium dose, body composition, acquisition time post bolus and
hematocrit. Measuring the ratio of T1 changes pre and post
Fig. 2 Native T1 maps (using ShMOLLI [12]), all with the same colour
scale. (a) healthy volunteer: the myocardium appears homogenously
green and the blood is red; low T1 values (blue) from iron overload (c)
and lipid storage in Fabry’s disease (c) (except the infero-lateral wall
which is high); (d) and (e) represent with high T1 values (red) in amyloid
(d) and inmyocarditis (d); infarcted (acute infarction) area appears red f) –
here basal anter-septum
Table 1 T1 mapping, ECVand cardiac diseases. Summary of T1 values
and ECV for different cardiac diseases
Cardiac disease Native T1 (msec) ECV (%)
Healthy volunteer ↔ ↔
Severe AS ↑ ↑
Chronic MI-LGE ↑↑ ↑↑↑






Iron overload ↓↓↓ ?
Legend: ↔ normal or↑increased or↓decreased T1/ECV; ? (as yet) not
known
*data from the septum of AFD patients without heart failure
**data currently only in abstract form
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contrast administration in the myocardium and blood provides
the partition coefficient, if a sufficient equilibrium of contrast
was reached between blood and myocardium [31]. When
corrected by hematocrit the myocardial extracellular volume
(ECV) is derived [14], biologically representing the myocar-
dial space fraction between cells; more specifically, the space
between all cells, including interstitial fluid and plasma be-
tween red cells in the myocardial capillaries. Three basic
methods have been used: a primed continuous infusion of
contrast to reach a definitive equilibrium of distribution be-
tween plasma and interstitium; a bolus only approach with
sufficient time to elapse post bolus for sufficient equilibrium;
and serial time point to curve fit. Currently, it appears that the
bolus only approach offers the simplest approach, but further
work is needed to clarify whether any incremental benefit of
the other two approaches is of sufficient merit [32, 33].
Expansion of the myocardial ECV represents a nonspecific
increase in free space between cells and occurs in a variety of
pathologies (Table 1). To distinguish, the degree of ECV
change and the clinical context is important. Cardiac AL
amyloid has a higher ECV than any other diseases generating
diagnostic specificity above a certain threshold and seems to
detect cardiac involvement earlier than other current tests —
and better than native T1 [34]. In absence of amyloid, the
increased ECV value expansion is mainly due to edema or
increased myocardial collagen. Edema has been little studied
to date. ECV imaging can quantitatively characterize infarcted
scar and atypical fibrosis, diffuse myocardial abnormalities—
even when not clinically apparent on LGE images— and also
the small changes occurring in myocardium with aging, even
if near to detection limit [35••, 36].
For low ECV expansion diseases, biases from blood pool
partial volume errors need to be meticulously addressed.
Nevertheless, even modest ECV changes appear prognostic.
In 793 consecutive patients (excluding amyloid and HCM,
measuring outside LGE areas) followed over 1 year, global
ECV predicted short term-mortality (Fig. 3) [37••]. The
same group also found (n~1000) higher ECVs in diabetics
associated with adverse outcome, including mortality and
heart failure hospitalization. Those on renin-angiotensin-
aldosterone system blockade had lower ECVs. ECV also
predicted mortality and/or incident hospitalization for HF
in diabetics [38•].
The continuous technical implementation has generated
automated parametric ECV maps, now available directly on
the scanner, where each pixel carries directly the ECV value
improving clinical utility and increasing the possibility to
integrate them in clinical protocol (Fig. 4) [39•].
T1 mapping is an exciting and novel tool and transition
from early development work to standardized methodologies
is crucial. Differences between vendors, sequences, field
strength and methodology generate confusion but also inno-
vation, so the early standardization steps are in the form of
consensus statements rather than guidelines and emphazise
areas where research is needed more so than approaches not to
pursue [40••].
Fig. 3 The ECV in non-scar
areas (LGE excluded) is
associated with all-cause
mortality even after relatively
short follow-up in all-comers to a
CMR service[37••]
Fig. 4 A severe aortic stenosis patient with moderate concentric LVH
and patchy scar on LGE imaging (a). Pre-contrast (b) and post-contrast T1
maps (c) and derived ECV map (d) add information: RV insertion point
native T1 elevation is seen (b) and there is diffuse extracellular expansion,
with an ECVof 32 %
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Myocardial Intracellular Volume (ICV)
(1-ECV) represents the myocardium not accessible to the
extracellular volume fraction. Accordingly, ICV represents
intact myocardial cellular component proving a way to
measure the cell volume. Again it is necessary to clarify
that there is a bias because, even if ICV mainly repre-
sent myocytes, it also includes fibroblasts, blood cells,
macrophage, etc.
ICV provides incremental information. In severe AS pa-
tients ECV has been found to be elevated but interestingly LV
hypertrophy regression after valvular replacement at 6 months
had no change in the ECV, but the ICV fell showing non-
invasively that early LVH regression was cellular rather than
fibrosis regression [41].
For HF, the above approaches are only now starting to be
applied. The ability to measure diffuse fibrosis and partition
the myocardium into cellular and extracellular compartments
is promising. Specifically, it may allow to personalise thera-
peutic approaches and to develop new therapies targeted either
to interstitial or intracellular pathways, but which may other-
wise fail if early development applies them indiscriminately to
an uncharacterised HF cohort. A number of studies are
planned or on their way currently.
Conclusions
Drug development strategies for HF have produced few
positive results over the last decade and HF continues to
represent an important problem in medicine with consid-
erable impact for health system cost. To ensure success in
mortality reduction a better understanding of disease path-
ways is needed in-vivo. CMR has established itself as the
gold standard for non-invasive myocardial tissue character-
ization and T1 mapping takes the technology a step fur-
ther, firstly, by measuring key processes in rare diseases
(iron, fat, amyloid), and secondly, by measuring diffuse
fibrosis, allowing us to dichotomize the myocardium into
its cellular and extra-cellular components, providing new
frontiers for pathologies understanding and identifying two
different therapeutic targets, cells and interstitium, with
high potential impact into our understanding of HF.
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